stoxline Quote Chart Rank Option Currency Glossary
  
Rhythm Pharmaceuticals, Inc. (RYTM)
43.33  1.54 (3.69%)    03-28 16:00
Open: 42.5
High: 43.66
Volume: 808,432
  
Pre. Close: 41.79
Low: 41.79
Market Cap: 2,606(M)
Technical analysis
2024-03-28 4:54:05 PM
Short term     
Mid term     
Targets 6-month :  55.29 1-year :  64.58
Resists First :  47.34 Second :  55.29
Pivot price 40.56
Supports First :  41.35 Second :  37.65
MAs MA(5) :  40.97 MA(20) :  40.91
MA(100) :  41.04 MA(250) :  28.81
MACD MACD :  -0.9 Signal :  -1.3
%K %D K(14,3) :  65.3 D(3) :  48.9
RSI RSI(14): 55.2
52-week High :  52.56 Low :  15.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RYTM ] has closed Bollinger Bands are 56.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 43.73 - 43.94 43.94 - 44.13
Low: 41.28 - 41.52 41.52 - 41.74
Close: 42.93 - 43.33 43.33 - 43.69
Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Thu, 28 Mar 2024
Should Biotechnology Stock Rhythm Pharmaceuticals Inc (RYTM) Be in Your Portfolio Thursday? - InvestorsObserver

Thu, 28 Mar 2024
Wellington Management Group LLP Lowers Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Wed, 27 Mar 2024
Whittier Trust Co. Purchases Shares of 2000 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mon, 25 Mar 2024
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific ... - Yahoo Finance

Sun, 24 Mar 2024
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $735599.90 in Stock - Defense World

Fri, 22 Mar 2024
Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 60 (M)
Shares Float 45 (M)
Held by Insiders 0.5 (%)
Held by Institutions 113.6 (%)
Shares Short 9,000 (K)
Shares Short P.Month 8,860 (K)
Stock Financials
EPS -3.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.85
Profit Margin -238.6 %
Operating Margin -170.3 %
Return on Assets (ttm) -32.3 %
Return on Equity (ttm) -85.1 %
Qtrly Rev. Growth 175.6 %
Gross Profit (p.s.) 0
Sales Per Share 1.28
EBITDA (p.s.) -3.04
Qtrly Earnings Growth 0 %
Operating Cash Flow -136 (M)
Levered Free Cash Flow -91 (M)
Stock Valuations
PE Ratio -13.55
PEG Ratio 1.1
Price to Book value 15.15
Price to Sales 33.65
Price to Cash Flow -19.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android